Shearman & Sterling represented UBS AG, BNP Paribas (Suisse) SA and Credit Suisse AG in connection with Amgen Inc.’s Regulation S offering of CHF 700 million aggregate principal amount of 0.410% notes due 2023. Amgen is a global biotechnology company that discovers, develops, manufactures and markets human therapeutics based on advances in cellular and molecular biology.

The Shearman & Sterling team was led by partner John Wilson (San Francisco-Capital Markets) and associates Nathan Mee and Scott Lucas (San Francisco-Capital Markets). Other key members of the team included partners Alan Seem (Menlo Park-Capital Markets), Laurence Crouch (Menlo Park-Tax) and Simon Letherman (London-Tax), counsel Eileen O’Pray (Menlo Park-Tax) and associates Gabriel Ng (London-Tax), Ryan Bray (Menlo Park-Tax) and Jeremy Cleveland (Menlo Park-Capital Markets).